| Drug General Information |
| Drug ID |
D0P1BK
|
| Former ID |
DNC001001
|
| Drug Name |
NC1153
|
| Drug Type |
Small molecular drug
|
| Indication |
Renal transplantation [ICD9: 279.5; ICD10:D89.8]
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C18H38Cl2N2O
|
| Canonical SMILES |
CN(C)CC1CCCCCCCCCC(C1=O)CN(C)C.Cl.Cl
|
| InChI |
1S/C18H36N2O.2ClH/c1-19(2)14-16-12-10-8-6-5-7-9-11-13-17(18(16)21)15-20(3)4;;/h16-17H,5-15H2,1-4H3;2*1H
|
| InChIKey |
GHMOOTNSJIQWGK-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
|
| Target and Pathway |
| Target(s) |
Tyrosine-protein kinase JAK3 |
Target Info |
Inhibitor |
[1]
|
|---|
|
KEGG Pathway
|
Chemokine signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
Signaling pathways regulating pluripotency of stem cells
|
|
Jak-STAT signaling pathway
|
|
Measles
|
|
HTLV-I infection
|
|
Epstein-Barr virus infection
|
|
Viral carcinogenesis
|
|
Primary immunodeficiency
|
|
PANTHER Pathway
|
Interleukin signaling pathway
|
|
JAK/STAT signaling pathway
|
|
PDGF signaling pathway
|
|
Pathway Interaction Database
|
IL4-mediated signaling events
|
|
CD40/CD40L signaling
|
|
Signaling events mediated by TCPTP
|
|
SHP2 signaling
|
|
IL2-mediated signaling events
|
|
IL2 signaling events mediated by PI3K
|
|
IL2 signaling events mediated by STAT5
|
|
Reactome
|
GPVI-mediated activation cascade
|
|
Interleukin-7 signaling
|
|
G beta:gamma signalling through PI3Kgamma
|
|
Interleukin-2 signaling
|
|
RAF/MAP kinase cascade
|
|
Interleukin receptor SHC signaling
|
|
WikiPathways
|
IL-2 Signaling Pathway
|
|
IL-4 Signaling Pathway
|
|
Interleukin-2 signaling
|
|
Interleukin-7 signaling
|
|
Oncostatin M Signaling Pathway
|
|
IL-9 Signaling Pathway
|
|
IL-7 Signaling Pathway
|
|
Interleukin-3, 5 and GM-CSF signaling
|
| References |
| REF 1 | Immunotherapy for De Novo renal transplantation: what's in the pipeline? Drugs. 2006;66(13):1665-84. |
|---|
